Integrated Universal
Experimentally-Validated
Artificial Intelligence
for Every Step of Pharmaceutical Research and Development
Our Mission is to accelerate drug discovery and drug development by continuously inventing and deploying New Artificial Intelligence technologies
We provide AI solutions to the top pharma and biotechnology companies to enable streamlined R&D efforts and transform the way therapeutics and materials are discovered.

Our automated, experimentally-certified AI platform enriches precision medicine to create and execute new promise to cut costs and development time substantially. By enabling the rapid discovery and development of novel molecules, we're ushering in new possibilities for the creation and discovery of a pipeline of therapeutic programs in cancer, fibrosis, anti-infective, immunology, and senescence.

Essentially, we aspire to be pioneers in this field, working relentlessly to innovate, publish proofs of concepts in scholarly publications, and delivering state-of-the-art AI solutions to top industry experts.
INTRODUCING FULLY-INTEGRATED DRUG DISCOVERY SOFTWARE SUITE
PHARMA.AI
operating system
  • Get published OMICs data deciphered
  • Analyse any OMICs data type
  • Evaluate drug targets
  • Get strategies for drug repurposing
  • Explore the power of automated
    end-to-end machine learning platform
  • Access structure-based and ligand-based drug design
  • Discover novel and diverse molecules
    for targets of interest
  • Predict clinical trial success rates
  • Identify the weak points in trial design
  • Adopt the best practices in the industry guided by InClinico
Expand your horizons
of data analysis and visualization
Explore an uncharted
chemical space
Design and predict
clinical trial outcomes
AI Pharma Pipeline
We explicitly strive to accelerate three areas of drug discovery and development: disease target identification, generation of synthetic biology (generative biology) and novel molecules (generative chemistry) data, and predicting clinical trial outcomes

Our revolutionary drug discovery engine utilizes millions of data samples and multiple data types to discover signatures of diseases and identify the most promising targets for billions of molecules that already exist or can be generated de novo with preferred sets of parameters
Over 150 Academic and Industry Collaborators Worldwide
Insilico Medicine has multiple global collaborations in the application of next-generation AI technologies such as reinforcement learning and generative adversarial networks to enable the generation of novel molecular structures with desired properties

These collaborations align with our aim of affiliating with the top companies and institutions to provide space-age solutions for drug discovery and biomarker development. Since our foundation in 2014, we have seen such partnerships grow, which has allowed us to get the right drugs to the right patients faster
We have assembled a highly skilled team of over 120 scientists, with about 70% appointed through hackathons and worldwide competitions in Rockville, Oxford, Warsaw, Brussels, Shanghai, Taipei, and Hong Kong. Our team of structural biologists, medical chemists, and machine learning experts are outstanding
© 2020 Insilico Medicine
INFO
  • Email: ai@insilico.com
  • 307A, Core Building 1, 1 Science Park East Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong
  • Privacy Policy
  • Cookies Policy